Asundexian

In OCEANIC-STROKE, patients who received asundexian after a non-cardioembolic ischemic stroke or high-risk transient ischemic attack were significantly less likely to suffer a secondary stroke compared to placebo, both in combination with antiplatelet therapy These results were consistent across all clinically relevant patient subgroups regardless of key patient characteristics like age or sex, the cause of stroke, or the severity of the stroke There was no increase in ISTH major bleeding, and the bleeding risk was similar to placebo for minor bleeding, hemorrhagic stroke, symptomatic intracranial hemorrhage, and fatal bleeding OCEANIC-STROKE enrolled 12,327 patients and is the first successfully completed Phase III trial of a FXIa inhibitor which demonstrated superiority in preventing stroke compared to placebo NEW ORLEANS--(BUSINESS WIRE)--Bayer today presented the results from the global, pivotal Phase III OCEANIC-STROKE study evaluating the use of its investigational, once-daily, oral, Factor XIa inhibitor asundexian (50mg) compared to placebo, both in combination with antiplatelet therapy. Asundexian significantly reduced ischemic stroke by 26% (csHR 0.74; 95% CI 0.65–0.84; p<.0001), in patients after a non-cardioembolic ischemic stroke or high-risk transient ischemic attack, with no increase in the risk of ISTH (International Society of Thrombosis and Hemostasis) major bleeding. These findings were consistent regardless of age or sex, index event (stroke or high-risk TIA), stroke subtype, NIHSS (National Institutes of Health Stroke Scale), and acute stroke therapy like thrombolysis or planned secondary prevention strategies SAPT or DAPT. The results were presented at the International Stroke Conference 2026 in New Orleans. OCEANIC-STROKE is the first successfully completed Phase III study of a Factor XIa inhibitor which demonstrated superiority in reducing recurrent ischemic stroke compared to placebo. “A stroke is a life-changing event for patients and a major public health burden. The findings from OCEANIC-STROKE are a notable research achievement, demonstrating a substantial reduction in the risk of stroke with asundexian compared to placebo, alongside a sustained treatment effect and a safety profile with no observed increase in ISTH major bleeding,” said Mike Sharma, M.D., Principal Investigator of the OCEANIC-STROKE study, Michael G. DeGroote Chair in Stroke Prevention, McMaster University and Senior Scientist at Population Health Research Institute, a joint institute of McMaster University and Hamilton Health Sciences. “For clinicians and researchers who have spent decades working to reduce the global burden of secondary stroke, the OCEANIC-STROKE results represent the kind of scientific progress the field has long been striving to achieve.” Alongside the primary findings, secondary endpoints showed asundexian reduced the risk of a stroke of any kind (ischemic and hemorrhagic) by 26% (6.6% vs. 8.8%; csHR 0.74; 95% CI, 0.65 to 0.84; p<.0001) compared to placebo. In addition, the following secondary efficacy endpoints were met for asundexian compared to placebo, both in combination with antiplatelet therapy: the composite endpoint of cardiovascular death, myocardial infarction (MI) or stroke, and the composite of death from any cause, MI or stroke. For the safety analyses, there was no increase in the rate of ISTH major bleeding between asundexian compared to placebo (1.9% vs. 1.7%; HR 1.10; 95% CI, 0.85–1.44). For the pre-specified secondary safety endpoints, the risk of bleeding was similar compared to the rates seen in the placebo arm. OCEANIC-STROKE enrolled all common stroke subtypes in its design, classified by the TOAST (Trial of Org 10172 in Acute Stroke Treatment) criteria. Among patients with an index ischemic stroke, the study enrolled patients with large-artery atherosclerosis (43%), small-vessel occlusion (lacune) (23%), stroke of undetermined etiology (30%), other determined etiology (3%), and cardioembolic stroke (2%). Across all TOAST subtypes evaluated, rates of recurrent ischemic stroke were lower with asundexian compared with placebo. “The consistent reduction in secondary events with asundexian across all types of strokes included in the trial, is particularly striking,” said Ashkan Shoamanesh, M.D., Co-Principal Investigator of OCEANIC-STROKE study and PHRI senior scientist. “OCEANIC-STROKE was deliberately designed with the goal of making the findings generalizable to the many ways stroke presents in clinical practice. These results provide confidence that, if approved, asundexian could become an important option for secondary stroke prevention across a broad range of stroke patients.” Each year, approximately 12 million people worldwide will experience a stroke, including nearly 800,000 people in the United States alone. Of these, 20-30% will be a recurrent stroke. Despite available secondary stroke prevention options, the risk of secondary stroke remains high. One in five stroke survivors will have another stroke within five years. Stroke is the second leading cause of death globally, and recurrent ischemic strokes tend to be more disabling and carry a higher mortality risk than the first stroke. “OCEANIC-STROKE marks an important milestone that reflects the scientific ambition of Bayer and the global study teams who came together to challenge the boundaries of stroke prevention research,” said Yesmean Wahdan, M.D., Senior Vice President, U.S. Medical Affairs, Bayer. “To share these results with the global stroke community is deeply rewarding and underscores Bayer’s continued commitment to advancing aspirational research in areas of thrombotic disease. Most importantly, we know these efforts may matter most for the many stroke survivors for whom reducing the risk of another stroke remains an urgent need.” Asundexian has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) as a potential treatment for stroke prevention in patients after a non-cardioembolic ischemic stroke. Asundexian is an investigational compound and has not been approved by any health authority for use in any country for any indication. About OCEANIC-STROKE The OCEANIC-STROKE study investigated the efficacy and safety of the oral Factor XIa inhibitor asundexian 50 mg once-daily compared to placebo, for prevention of ischemic stroke in patients after a non-cardioembolic ischemic stroke or high-risk transient ischemic attack (TIA) in combination with antiplatelet therapy. It is a multicenter, international, randomized, placebo-controlled, double-blind, parallel group and event-driven study, that randomized 12,327 participants worldwide. The primary endpoint was time to ischemic stroke; the primary safety endpoint was major bleeding. About FXIa inhibitors Factor XIa (FXIa) is a protein in the blood coagulation pathway with different roles in hemostasis and thrombosis. FXIa has a minor role in the formation of a hemostatic plug that seals the leak at the site of vessel injury. About Bayer’s Commitment in Cardiovascular and Cerebrovascular Medicine Bayer is a leader in cardiology and is advancing a portfolio of innovative treatments in cardiovascular (CV) and cerebrovascular diseases of high unmet medical need. We have set a clear focus on developing innovative therapies to treat such diseases (e.g., stroke, heart failure, cardiomyopathies, and chronic kidney disease) and it is our ambition to take a leading role in the care of patients with these diseases. Bayer is actively shaping the future of cardiology and neurology with a robust and diversified pipeline, strategically positioned to address critical unmet needs and drive significant long-term value. Bayer’s portfolio already includes several innovative products and compounds in various stages of preclinical and clinical development. About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2024, the Group employed around 93,000 people and had sales of 46.6 billion euros. R&D expenses amounted to 6.2 billion euros. For more information, go to www.bayer.com. Find more information at: Health for all, Hunger for none | Bayer United States Follow us on Facebook: http://www.facebook.com/bayer Follow us on LinkedIn: Bayer | Pharmaceuticals Forward-Looking Statements This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Guggenheim Securities analysts valued the stroke opportunity at $3 billion to $4 billion. \n Bayer has linked asundexian to a 26% reduction in stroke in a phase 3 study, setting the bar for Bristol Myers Squibb and Johnson & Johnson’s rival factor XIa inhibitor in a blockbuster indication. The German drugmaker reported the study met its primary endpoint in November, providing a boost for the program and factor XIa inhibition more broadly after setbacks to asundexian and BMS and J&J’s rival drug candidate milvexian. Yet the lack of data in Bayer’s top-line release left unanswered questions about the clinical significance of the statistical success. Bayer answered the questions Thursday, using the International Stroke Conference 2026 in New Orleans to present data from the trial. The headline finding is that asundexian cut ischemic stroke by 26% after a noncardioembolic ischemic stroke or high-risk transient ischemic attack (TIA), also called a mini-stroke.On an earnings call in May, Stefan Oelrich, head of Bayer’s pharma division, said the company focused the phase 3 trial on the subgroup in which it saw the biggest effect in phase 2. The company reported a 36% reduction in the risk of recurrent symptomatic ischemic stroke and TIA in the phase 2 subgroup. For comparison, BMS and J&J saw a 30% relative risk reduction in symptomatic ischemic strokes in their phase 2 trial. Asundexian reduced the stroke rate in the phase 3 trial without increasing major bleeding, which affected 1.9% of people on the study drug and 1.7% of their counterparts on placebo. Bayer said the risks of minor bleeding, hemorrhagic stroke, symptomatic intracranial hemorrhage and fatal bleeding were similar on asundexian and placebo.The potential to clear clots without raising bleeding risk is central to the promise of factor XIa inhibitors. While other anticoagulants affect hemostasis and thrombosis, factor XIa inhibition could decouple the mechanisms to deliver at least comparable efficacy and better safety than existing treatments.Bayer reported the phase 3 trial met multiple secondary endpoints, including by linking asundexian to a 26% reduction in the risk of a stroke of any kind compared to placebo. The secondary analysis included hemorrhagic strokes. Bayer also hit a composite endpoint of cardiovascular death, myocardial infarction (MI) or stroke as well as the composite of death from any cause, MI or stroke.Ashkan Shoamanesh, M.D., the trial’s co-principal investigator, said in a statement that the consistent reduction in secondary events with asundexian across all types of strokes is particularly striking. The results provide confidence that asundexian, if approved, could be an important option for secondary stroke prevention across a broad range of patients, Shoamanesh said. At the J.P. Morgan Healthcare Conference in January, Bayer\'s Oelrich said the pharma was engaging with health authorities and aiming to win approval this year. The timeline would put Bayer “well ahead of any competitor in this space, which will allow us to clearly set the scene and once again prove what I call our secret sauce in cardiovascular because we believe that we\'re a true leader in this space,” Oelrich said.BMS and J&J expect to publish phase 3 results for milvexian in secondary stroke prevention in the second half of 2026. The companies are gearing up to compete for a stroke market that Guggenheim Securities analysts valued at $3 billion to $4 billion in a note to investors in November. The analysts estimated atrial fibrillation, where Bayer has already failed, is a $15 billion opportunity.